Perrigo Completes Divestiture of Dermacosmetics Business

Rhea-AI Summary

Perrigo (NYSE: PRGO) completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, consisting of €305.6 million upfront (including €5.6 million net working capital adjustment) and up to €27.0 million contingent over three years. Brands sold include ACO, Biodermal, Emolium, and Iwostin. Perrigo reported the divested unit had ~€120 million in 2025 net sales and represented ~5% of adjusted operating income. Perrigo said net proceeds will be used primarily to reduce debt and strengthen the balance sheet.

Positive

• Upfront net proceeds of €305.6M
• Total consideration up to €332.6M
• Divested unit generated €120M in 2025 net sales
• Sale expected to reduce debt and enhance flexibility

Negative

• Loss of a branded business with €120M annual sales
• Contingent €27.0M dependent on future net sales performance

News Market Reaction – PRGO

+0.68%

1 alert

+0.68% News Effect

On the day this news was published, PRGO gained 0.68%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Total consideration: €332.6 million Upfront cash: €305.6 million Contingent consideration: €27.0 million +5 more

8 metrics

Total consideration €332.6 million Maximum consideration for Dermacosmetics divestiture

Upfront cash €305.6 million Cash proceeds including €5.6 million net working capital adjustment

Contingent consideration €27.0 million Earn-out tied to net sales milestones over next three years

Dermacosmetics net sales €120 million Calendar year 2025 net sales of divested business

Dermacosmetics share of AOI 5% Portion of Perrigo adjusted operating income from Dermacosmetics in 2025

FY 2025 net sales $4,253.1 million Consolidated continuing operations, twelve months ended Dec 31, 2025

Adjusted operating income $622.3 million Consolidated continuing operations, FY 2025

Goodwill impairment $1.3 billion Total goodwill impairment included in FY 2025 impairment charges

Market Reality Check

Price: $11.92 Vol: Volume 2,388,524 is below...

normal vol

$11.92 Last Close

Volume Volume 2,388,524 is below the 20-day average of 2,737,063 (relative volume 0.87). normal

Technical Price at $11.84 is trading below the 200-day moving average of $17.01 and far under the $28.44 52-week high.

Peers on Argus

PRGO fell 1.91% while key peers like PBH (+1.02%), AMRX (+0.78%), INDV (+2.25%) ...

PRGO fell 1.91% while key peers like PBH (+1.02%), AMRX (+0.78%), INDV (+2.25%) and HCM (+0.52%) mostly traded higher; only BHC declined (-2.22%). This points to a stock-specific move rather than a sector-wide shift.

Common Catalyst Peer headlines today are earnings-focused, with several consumer health names highlighting quarterly results and guidance.

Historical Context

5 past events · Latest: Apr 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 29	Dividend declaration	Positive	-1.9%	Announced quarterly cash dividend of $0.29 per share, $1.16 annually.
Apr 22	Earnings date set	Neutral	-0.2%	Scheduled Q1 2026 results release and conference call on May 6, 2026.
Mar 03	Conference presentation	Neutral	+2.6%	CEO presentation at UBS Global Consumer and Retail Conference on strategy.
Feb 26	Earnings results	Neutral	-1.5%	Reported FY 2025 results with $4.25B sales, $1.3B goodwill impairment, EPS $2.75.
Feb 19	Dividend declaration	Positive	+2.1%	Announced $0.29 quarterly dividend, $1.16 annualized, reaffirming payout.

Pattern Detected

Recent news shows mixed reactions: dividend announcements have produced both gains and losses, while conference and earnings updates often saw modest positive moves.

Recent Company History

Over recent months, Perrigo has focused on shareholder returns and communication, with two $0.29 quarterly dividend declarations and an upcoming Q1 2026 earnings release on May 6, 2026. The company presented its consumer health strategy at the UBS Global Consumer and Retail Conference and reported FY 2025 results showing $4.25B in net sales, a $1.3B goodwill impairment, and adjusted EPS of $2.75. Today’s divestiture fits the ongoing effort to streamline the portfolio and focus on core self-care categories.

Market Pulse Summary

This announcement details the completed sale of Perrigo’s Dermacosmetics business for up to €332.6 m...

Analysis

This announcement details the completed sale of Perrigo’s Dermacosmetics business for up to €332.6 million, including €305.6 million in upfront cash and potential earn-outs. The divested unit contributed about €120 million of 2025 net sales and 5% of adjusted operating income. Management highlighted using proceeds primarily for debt reduction. Against prior disclosures of $4,253.1 million in FY 2025 net sales and a large goodwill impairment, investors may monitor leverage trends and core self-care growth following this portfolio reshaping.

Key Terms

net working capital, contingent, non-gaap financial measure, generally accepted accounting principles (gaap), +4 more

8 terms

net working capital financial

"including €5.6 million in net working capital adjustments, and up to an additional"

Net working capital is the amount left when you subtract a company’s short-term bills (like accounts payable and short-term loans) from its short-term assets (cash, money owed to it, and inventory). Think of it as the cash cushion a business has to keep daily operations running — a bigger cushion means fewer short-term funding worries, while a small or negative number can signal pressure to raise cash or cut activity, which matters to investors assessing stability and short-term risk.

contingent financial

"up to an additional €27.0 million contingent on the achievement of net sales"

"Contingent" describes something that depends on certain conditions or events happening first. For investors, it often relates to situations where a particular outcome or benefit will only occur if specific circumstances are met, similar to a promise that only activates if certain conditions are fulfilled. This means the value or occurrence of the item is uncertain and relies on future developments.

non-gaap financial measure financial

"This press release contains certain non-GAAP measures. A "non-GAAP financial measure""

A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.

generally accepted accounting principles (gaap) financial

"presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP)"

A set of standardized rules and methods companies use to prepare and report financial statements, like a common recipe or rulebook for presenting money matters. It helps ensure numbers are prepared consistently so investors can compare results, spot trends, and judge a company’s health without being misled by different accounting tricks. Reliable, comparable reports make investment decisions and valuations more informed and less risky.

adjusted operating income financial

"Adjusted Operating Income | | $ 622.3"

Adjusted operating income is a company's profit from its main activities, excluding certain one-time or unusual costs and gains. It helps investors see how well the business is performing in its normal operations, without distractions from rare events or expenses. This way, they get a clearer picture of the company’s true profitability.

goodwill impairment financial

"due primarily to a total goodwill impairment of $1.3 billion and the existence"

Goodwill impairment occurs when a company’s valued reputation or brand strength, known as goodwill, is found to be worth less than previously recorded on its financial statements. This usually happens when the company's performance declines or market conditions change, signaling that the expected benefits from acquisitions or brand value are no longer as strong. It matters to investors because it can indicate that a company's assets are less valuable than initially thought, potentially affecting its overall financial health.

equity method investment financial

"existence of an other-than-temporary impairment of our equity method investment in"

An equity method investment is an accounting way to report ownership in another company when an investor has significant influence (commonly around 20–50% of voting rights). Instead of listing the other company’s full assets and debts, the investor records its share of that company’s profits or losses on its own income statement—like keeping track of your share of a neighborhood bakery’s monthly earnings. Investors care because those shared profits, losses and changes in the investee’s value directly affect the investor’s reported earnings and balance sheet, so this method can materially change a company’s financial picture and valuation.

other-than-temporary impairment financial

"the existence of an other-than-temporary impairment of our equity method investment"

Other-than-temporary impairment is an accounting write-down taken when a company concludes that an asset—most often an investment or loan—has lost value that is unlikely to recover. For investors, it matters because the write-down reduces reported profits and the company’s net worth and can signal lasting credit or portfolio problems, similar to recognizing a car has been permanently damaged and selling it for much less.

AI-generated analysis. Not financial advice.

• Advances key Three-S plan pillar, streamlining portfolio
• Upfront net proceeds of approximately €306 million will enable debt reduction

DUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sales milestones over the next three years. Brands sold in the transaction include ACO, Biodermal, Emolium, and Iwostin.

"This transaction marks another important milestone in the execution of our Three-S plan to Stabilize, Streamline, and Strengthen the Company," said Patrick Lockwood-Taylor, President and Chief Executive Officer. "By further streamlining our portfolio and sharpening our focus on core categories, we are better positioned to leverage our competitive advantages and deliver more consistent and sustainable growth in shareholder value. Importantly, we expect the net proceeds from this transaction will be used primarily to reduce debt, enhancing our financial flexibility and strengthening our balance sheet."

In calendar year 2025, Perrigo's Dermacosmetics branded business generated approximately €120 million in net sales and represented approximately 5% of Perrigo's adjusted operating income.

Advisors

Greenhill & Co., an affiliate of Mizuho, is serving as financial advisor to Perrigo, and Latham & Watkins is serving as legal advisor.

About Perrigo

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.

For more information, visit www.perrigo.com. 

Non-GAAP Measures

This press release contains certain non-GAAP measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts different from the most directly comparable measure calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP) in the statements of operations, balance sheets or statements of cash flows of the Company. Pursuant to the requirements of the U.S. Securities and Exchange Commission, the Company has provided reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures referred to in this press release.

These non-GAAP financial measures should be considered as supplements to the GAAP reported measures, should not be considered replacements for, or superior to the GAAP measures and may not be comparable to similarly named measures used by other companies.

Perrigo Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including the Company's ability to realize the anticipated benefits of the divestiture, including the expected impact on its portfolio focus, financial flexibility, debt reduction, and balance sheet; the timing, amount and certainty of receipt of any contingent consideration under the transaction, which is subject to the future net sales performance of the disposed business; the actual use of net proceeds from the transaction; the effects of macroeconomic conditions, foreign currency exchange rates and tax matters related to the transaction; and general market, economic, competitive and operational conditions. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025 and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Perrigo Contacts

Eric Jacobson, Vice President, Global Investor Relations
eric.jacobson@perrigo.com 

Nick Gallagher, Associate Director, Global Investor Relations
nicholas.gallagher@perrigo.com 

TABLE I
PERRIGO COMPANY PLC
RECONCILIATION OF NON-GAAP MEASURE
(in millions)
(unaudited)
	Twelve Months Ended December 31, 2025
Consolidated Continuing Operations	Net  Sales		Operating Income
Reported	$           4,253.1		$   (1,122.2)
As a % of reported net sales			(26.4) %
Pre-tax adjustments:
Amortization expense related primarily to acquired intangible assets			223.5
Restructuring charges and other termination benefits			71.9
Unusual litigation			59.0
Impairment charges(1)			1,363.1
Infant formula remediation			0.9
Other(2)			26.1
Adjusted Operating Income			$        622.3
As a % of reported net sales			14.6 %
Adjusted Operating Income in Euros(3)			€        551.4

(1)	During the twelve months ended December 31, 2025 impairment charges were due primarily to a total goodwill impairment of $1.3 billion and the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million.
(2)	Other pre-tax adjustments for the twelve months ended December 31, 2025 are partly due to $12.2 million of professional  consulting fees for potential divestiture activity.
(3)	Adjusted Operating Income was translated at the average exchange rate for the 2025 calendar year of 0.8860 EUR per USD.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/perrigo-completes-divestiture-of-dermacosmetics-business-302759218.html

SOURCE Perrigo Company plc

FAQ

What did Perrigo (PRGO) sell in the April 30, 2026 divestiture?

Perrigo sold its branded Dermacosmetics business, including ACO, Biodermal, Emolium, and Iwostin. According to the company, the buyer is Karo Healthcare and the deal transfers those brands and related operations to the purchaser.

How much did Perrigo (PRGO) receive from the Dermacosmetics sale?

Perrigo received €305.6 million in upfront cash and up to €27.0 million contingent consideration. According to the company, total consideration is up to €332.6 million, with contingents payable if net sales milestones are met over three years.

What was the Dermacosmetics unit's revenue contribution to Perrigo in 2025?

The divested Dermacosmetics business generated approximately €120 million in net sales in 2025. According to the company, that represented about 5% of Perrigo's adjusted operating income for the period.

How will Perrigo (PRGO) use the proceeds from the sale?

Perrigo said the net proceeds will be used primarily to reduce debt and strengthen the balance sheet. According to the company, the transaction is intended to enhance financial flexibility as part of its Three-S plan.

Is any of the consideration for Perrigo (PRGO) contingent after closing?

Yes. Up to €27.0 million is contingent on achieving specified net sales milestones over the next three years. According to the company, receipt of contingent payments depends on the future net sales performance of the disposed business.

Who advised Perrigo (PRGO) on the Dermacosmetics divestiture?

Financial advisor to Perrigo was Greenhill & Co., an affiliate of Mizuho, and legal advisor was Latham & Watkins. According to the company, these firms advised on transaction execution and documentation.